First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...
The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients ...
Metastatic urothelial carcinoma (mUC) is a characteristically aggressive tumor with high rates of visceral disease. 4 Patients with mUC face important challenges that result in poor survival outcomes, ...
Chemotherapy regimen shows potential to improve survival and reduce need for surgery in patients with muscle-invasive bladder ...
The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or ...
China NMPA approves Astellas Pharma’s Padcev in combination with Keytruda to treat advanced bladder cancer: Tokyo Thursday, January 9, 2025, 09:00 Hrs [IST] Astellas Pharma Inc.
On Janurary 7th, 2025, Annals of Oncology (IF: 56.7), a top oncology journal globally, published remarkable long-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback